Raha Samraat S. 4

What Happened

• Raha Samraat, President & CEO and a director of Myriad Genetics (MYGN), was granted 618,557 restricted stock units (RSUs) on March 12, 2026 (reported as an award, code A, $0.00 per share).
• On March 13 and March 14, 2026, a total of 47,120 shares (36,304 and 10,816 shares) were withheld/disposed to satisfy tax withholding obligations at $4.66 per share, totaling $219,580 (codes F; amounts reported as $169,177 and $50,403).

Key Details

• Transaction dates and prices:
  • 2026-03-12: RSU grant — 618,557 units @ $0.00 (award).
  • 2026-03-13: 36,304 shares withheld @ $4.66 = $169,177.
  • 2026-03-14: 10,816 shares withheld @ $4.66 = $50,403.
• Total shares withheld for taxes: 47,120; total withholding value: $219,580.
• Shares owned after transactions: not stated in the provided filing excerpt.
• Footnotes:
  • F1: The 618,557 units are time‑based RSUs under the company’s 2017 Equity Incentive Plan; each RSU vests in three equal annual installments beginning one year after grant.
  • F2: The withheld shares were used to satisfy tax withholding on vested RSUs; the number withheld was based on the March 13, 2026 closing price.
• Filing: Form 4 filed March 16, 2026, reporting transactions dated March 12–14, 2026; filing appears timely based on report dates.

Context

• The March 12 entry is a grant of RSUs (future shares contingent on vesting), not an open‑market purchase. The March 13–14 entries are tax‑withholding dispositions (routine) related to prior RSU vesting, not necessarily a signal of buying/selling intent in the market.
• For retail investors, awards signal potential future dilution as RSUs vest; withholding of shares to cover taxes is a common administrative step and typically does not reflect a change in insider sentiment.